MedTrace Logo

Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)

NCT02018315 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-10-31

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain.

The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe and potentially promising by supplying anaplerotic precursors through metabolism of odd-carbon fatty acids that can enter the citric acid cycle (CAC) through alternative metabolic pathways.

Conditions

  • Glucose Transporter Type 1 Deficiency Syndrome
  • GLUT1 Deficiency Syndrome

Interventions

DRUG

Triheptanoin

Triheptanoin is a 7-carbon medium chain triglyceride

Sponsors & Collaborators

  • Juan Pascual

    lead OTHER

Principal Investigators

  • Juan M. Pascual, MD, PhD · UT Southwestern Medical Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-01-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018315 on ClinicalTrials.gov